Related Experiment Video
Updated: Jun 1, 2025

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
Published on: April 18, 2016
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function
Gengwen Tian1,2, Gabriel A Barragan1, Hangjin Yu1
1Department of Pediatrics, Center for Advanced Innate Cell Therapy, Texas Children's Cancer and Hematology Center, Houston, Texas.
Abstract:
Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in the regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that uses a guide RNA (gRNA) library targeting 1,118 immune-related genes. Unmodified NKTs and NKTs expressing a GD2-specific chimeric antigen receptor (GD2.CAR) were transduced with the gRNA library and exposed to CD1d+ leukemia or CD1d-GD2+ neuroblastoma cells, respectively, over six challenge cycles in vitro. Quantification of gRNA abundance revealed enrichment of PRDM1-specific gRNAs in both NKTs and GD2.CAR NKTs, a result that was validated through targeted PRDM1 knockout. Transcriptional, phenotypic, and functional analyses demonstrated that CAR NKTs with PRDM1 knockout underwent central memory-like differentiation and resisted exhaustion. However, these cells downregulated the cytotoxic mediator granzyme B and showed reduced in vitro cytotoxicity and only moderate in vivo antitumor activity in a xenogeneic neuroblastoma model. In contrast, short hairpin RNA-mediated PRDM1 knockdown preserved effector function while promoting central memory differentiation, resulting in GD2.CAR NKTs with potent in vivo antitumor activity. Thus, we have identified PRDM1 as a regulator of NKT memory differentiation and effector function that can be exploited to improve the efficacy of NKT-based cancer immunotherapies.
Insights
Researchers identified PRDM1 as a key regulator of Natural Killer T cell (NKT) function. Modulating PRDM1 levels can enhance NKT-based cancer immunotherapies by improving memory differentiation and antitumor activity.
Area of Science:
- Immunology
- Cancer Biology
- Genetic Engineering
Background:
- Natural Killer T cells (NKTs) show promise for cancer immunotherapy.
- Identifying regulators of NKT functional fitness is crucial for enhancing therapeutic efficacy.
- Limited knowledge exists regarding genes controlling NKT therapeutic activity.
Purpose of the Study:
- To discover novel regulators of NKT cell functional fitness.
- To investigate the role of PRDM1 in NKT cell differentiation and effector function.
- To explore strategies for improving NKT-based cancer immunotherapies.
Main Methods:
- CRISPR/Cas9-based mutagenesis screen targeting 1,118 immune-related genes.
- Transduction of NKTs and GD2.CAR NKTs with a guide RNA library.
- In vitro co-culture challenges with leukemia and neuroblastoma cells.
- PRDM1 knockout and knockdown validation.
- Transcriptional, phenotypic, and functional analyses.
Main Results:
- Enrichment of PRDM1-specific guide RNAs identified PRDM1 as a regulator.
- PRDM1 knockout in CAR NKTs promoted memory differentiation and resistance to exhaustion but reduced cytotoxicity.
- Short hairpin RNA-mediated PRDM1 knockdown preserved effector function and enhanced in vivo antitumor activity.
- PRDM1 regulates both NKT memory differentiation and effector function.
Conclusions:
- PRDM1 is a critical regulator of NKT cell memory differentiation and effector function.
- Targeting PRDM1 offers a potential strategy to optimize NKT-based cancer immunotherapies.
- PRDM1 modulation can be exploited to enhance the therapeutic efficacy of NKT cells in cancer treatment.
More Related Videos
06:12Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
Published on: March 7, 2022
07:17Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
Published on: June 22, 2016
Related Concept Videos
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Negative Regulator Molecules
Abnormal Proliferation
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Regulation of the Unfolded Protein Response
Positive Regulator Molecules